Udvalget for Humanmedicinske Lægemidler (CHMP) bemærkede, at Stelara har en ny virkemåde, som blokerer to signalstoffers aktiviteter (interleukin 12 og interleukin 23) frem for kun et signalstofs aktiviteter.
The Committee for Medicinal Products for Human Use (CHMP) noted that Stelara has a new mode of action, blocking the activity of two messenger molecules (interleukin-12 and interleukin-23) rather than only one.